nav-left cat-right
cat-right

GALAPAGOS NV & ASINEX LTD. INITIATE DRUG DISC...

Mechelen, Belgium & Moscow, Russia, 12 May 2005 – Galapagos NV, a genomics-based drug discovery company and ASINEX Ltd, a worldwide leader in lead generation and optimization announce that they have initiated an integrated drug discovery collaboration in bone and joint diseases. The collaboration will result in a set of optimized leads for Galapagos’ validated bone and joint disease drug targets. Financial...

Emerging Drug Discovery Technologies: Building Com...

DUBLIN, Ireland, May 6 /PRNewswire/ — Research and Markets (http://www.researchandmarkets.com/reports/c17061 ) has announced the addition of Emerging Drug Discovery Technologies: Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi to their offering. Emerging Drug Discovery Technologies: Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi, is a new report which provides...

Definiens and Cenix BioScience Enter Into Licensin...

The two companies’ offerings are ideally complementary and the agreement will therefore build on their inherent synergies. Cenix is providing research services for the life science industry and academic groups, focusing on the combination of high throughput (HT) RNAi with high content (HC) assays in human and rodent cells. For those groups capable of carrying out such large scale studies themselves, Definiens is...

QIAGEN Acquires RNAture’s Portfolio of Nucleic A...

Products Address High-Throughput mRNA Purification for Gene Expression Analysis Venlo, The Netherlands – May 2, 2005 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA), the world’s leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins today announced the acquisition of the world-wide, exclusive rights and...

Protagen AG installs new management and board of d...

Dortmund (April 14, 2005) – Protagen closed a first financing round with the VC S-VentureCapital Dortmund for the expansion of its protein biochip business. In the course of this capital influx, positions in the management and the board of directors have been reorganized. Dr. Stefan Muellner has taken over the position of the CSO in the board of Protagen AG. Dr. Muellner brings a lot of experience from positions in...

Trigen and ProCorde Merge to Create Europe’s...

Complete pipeline of novel, competitive, clinical-stage products addressing major in-hospital and out-patient thrombosis markets — Extensive portfolio of pre-clinical and discovery-stage programmes and platforms targeting cardiovascular diseases — Complementary expertise with resulting competences in discovery, development and commercialisation of small molecules and protein therapeutics —...
Page 61 of 61« First...102030...5758596061